1. Home
  2. MGX vs BEDU Comparison

MGX vs BEDU Comparison

Compare MGX & BEDU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MGX
  • BEDU
  • Stock Information
  • Founded
  • MGX 2018
  • BEDU 1994
  • Country
  • MGX United States
  • BEDU United Kingdom
  • Employees
  • MGX N/A
  • BEDU N/A
  • Industry
  • MGX
  • BEDU Other Consumer Services
  • Sector
  • MGX
  • BEDU Real Estate
  • Exchange
  • MGX NYSE
  • BEDU Nasdaq
  • Market Cap
  • MGX 62.1M
  • BEDU 47.7M
  • IPO Year
  • MGX 2024
  • BEDU 2017
  • Fundamental
  • Price
  • MGX $2.28
  • BEDU $1.79
  • Analyst Decision
  • MGX Strong Buy
  • BEDU
  • Analyst Count
  • MGX 4
  • BEDU 0
  • Target Price
  • MGX $13.00
  • BEDU N/A
  • AVG Volume (30 Days)
  • MGX 690.3K
  • BEDU 3.4K
  • Earning Date
  • MGX 08-13-2025
  • BEDU 08-01-2025
  • Dividend Yield
  • MGX N/A
  • BEDU N/A
  • EPS Growth
  • MGX N/A
  • BEDU N/A
  • EPS
  • MGX N/A
  • BEDU N/A
  • Revenue
  • MGX $45,263,000.00
  • BEDU $224,321,752.00
  • Revenue This Year
  • MGX N/A
  • BEDU N/A
  • Revenue Next Year
  • MGX $11.75
  • BEDU N/A
  • P/E Ratio
  • MGX N/A
  • BEDU N/A
  • Revenue Growth
  • MGX N/A
  • BEDU N/A
  • 52 Week Low
  • MGX $1.23
  • BEDU $1.35
  • 52 Week High
  • MGX $5.50
  • BEDU $2.41
  • Technical
  • Relative Strength Index (RSI)
  • MGX 78.35
  • BEDU 53.41
  • Support Level
  • MGX $1.45
  • BEDU $1.70
  • Resistance Level
  • MGX $1.70
  • BEDU $1.90
  • Average True Range (ATR)
  • MGX 0.14
  • BEDU 0.04
  • MACD
  • MGX 0.07
  • BEDU 0.00
  • Stochastic Oscillator
  • MGX 92.56
  • BEDU 56.00

About MGX METAGENOMI INC

Metagenomi Inc is a genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived genome editing toolbox. The genome editing toolbox includes systems for making small edits such as programmable nucleases, base editors, small RNA-mediated integration systems (RIGS), as well as large gene integration systems including large template RIGS and CRISPR-associated transposases (CASTs). The company is focused on its vivo gene editing for its wholly-owned pipeline while pursuing technology out licensing for ex vivo cell therapy. Its pipeline includes product candidates aimed at addressing disorders like Hemophilia A (through MGX-001), Refractory Hypertension, Cardiovascular diseases, and Wilson's disease, among others.

About BEDU Bright Scholar Education Holdings Limited each representing four

Bright Scholar Education Holdings Ltd operates as an education service provider. It is engaged in the provision of education services, including complementary education services, operation services for domestic schools, and education programs and services including independent schools and colleges in United Kingdom (the UK) and the United States (the U.S.) Kingdom. It nearly eight overseas school located in the United Kingdom and the United States. It has three reportable segments, including Overseas Schools, Complementary Education Services, and K-12 Operation Services. Key revenue is generated from Overseas Schools. From a geographical perspective: Key revenue is generated from China following UK, U.S., Canada and Singapore.

Share on Social Networks: